Glenmark Pharmaceuticals Q2 FY27: revenue down 29.8% to ₹4,247 Cr, net profit down 56.8% to ₹264 Cr
Results · Finvezto · 5 Nov 2026 · Glenmark Pharmaceuticals (GLENMARK)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 4,247 | - | -29.8% |
| Operating profit | 864 | - | - |
| Net profit | 264 | -45.4% | -56.8% |
| Operating margin | 20.3% | - | - |
| Net margin | 6.2% | - | -3.9 pp |
YoY is the company's own figure. QoQ shows where our quarterly series matches the filing.
Key points
- Glenmark Pharmaceuticals reported consolidated revenue of Rs 4,247.30 crore for Q2 FY27, down 29.8% YoY from Rs 6,046.90 crore, with EBITDA at Rs 863.80 crore and reported PAT at Rs 263.80 crore. NSE filing
- On a like-for-like basis, consolidated revenue grew approximately 20% YoY, while adjusted PAT stood at Rs 485.20 crore. NSE filing
- Revenue was ₹4,247 Cr, down 29.8% on a year earlier. Finvezto data
Links
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.